Skip to main content

Table 3 Ongoing trials investigating the combination therapy of ICIs

From: Emerging treatment modalities for systemic therapy in hepatocellular carcinoma

Checkpoint inhibitors

Phase

Patients (No.)

Clinical setting

Status

NCT numbers

Nivolumab + Ipilimumab

I/II

32

Child-Pugh A HCC

Recruiting

NCT03682276

Nivolumab + Ipilimumab

I

50

Unresectable HCC with Child Pugh Class A cirrhosis

Active, not recruiting

NCT03203304

Nivolumab + Ipilimumab

II

30

HCC with potential surgical resection

Active, not recruiting

NCT03222076

Nivolumab + Ipilimumab

III

650

Advanced HCC without prior systemic therapy

Recruiting

NCT04039607

Nivolumab + Ipilimumab

II

40

HCC with potential for curative surgical resection

Recruiting

NCT03510871

Nivolumab + Mogamulizumab

I

96

locally advanced or metastatic solid tumors

Completed

NCT02476123

Nivolumab + Relatlimab

I

20

Potentially resectable HCC

Not yet recruiting

NCT04658147

Pembrolizumab + Bavituximab

II

28

Locally advanced or metastatic HCC not amenable to locoregional therapy

Recruiting

NCT03519997

Durvalumab+ Tremelimumab

III

1504

Unresectable HCC without prior systemic therapy

Recruiting

NCT03298451

Durvalumab+ Tremelimumab

I

32

Unresectable, locally advanced liver cancer after radioembolization

Suspended

NCT04605731

Durvalumab+ Tremelimumab

II

433

Advanced HCC

Active, not recruiting

NCT02519348